Stockreport

BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia

BioXcel Therapeutics, Inc.  (BTAI) 
Last bioxcel therapeutics, inc. earnings: 11/14 07:00 am Check Earnings Report
PDF Company plans to initiate trial following recent meeting with FDA No FDA-approved therapies for acute treatment of AAD are currently available NEW HAVEN, Conn., April [Read more]